RT @OncoAlert: The 2⃣nd paper of the @OncoAlert 🚨 @CD_AACR Academic Recap has been chosen On March 3⃣1⃣st Our OncoAlert🌐Colleague @neera…
RT @OncoAlert: The 2⃣nd paper of the @OncoAlert 🚨 @CD_AACR Academic Recap has been chosen On March 3⃣1⃣st Our OncoAlert🌐Colleague @neera…
RT @OncoAlert: The 2⃣nd paper of the @OncoAlert 🚨 @CD_AACR Academic Recap has been chosen On March 3⃣1⃣st Our OncoAlert🌐Colleague @neera…
PROXIMAMENTE @OncoAlert 🚨 @CD_AACR Academic Recap!! con @neerajaiims Marzo 31, 2021
The 2⃣nd paper of the @OncoAlert 🚨 @CD_AACR Academic Recap has been chosen On March 3⃣1⃣st Our OncoAlert🌐Colleague @neerajaiims 👨⚕️🇺🇸of @Huntsman_GU will discuss "Targeting p300/CBP axis in lethal #ProstateCancer" by de Bono & team Stay tuned‼️#P
RT @CD_AACR: ICYMI: Targeting p300/CBP in lethal #prostatecancer. @AdamSharpMedOnc @Nb10Nigel @NeilPegg1 @royalmarsdenNHS @ICR_London http…
RT @CD_AACR: ICYMI: Targeting p300/CBP in lethal #prostatecancer. @AdamSharpMedOnc @Nb10Nigel @NeilPegg1 @royalmarsdenNHS @ICR_London http…
RT @CD_AACR: ICYMI: Targeting p300/CBP in lethal #prostatecancer. @AdamSharpMedOnc @Nb10Nigel @NeilPegg1 @royalmarsdenNHS @ICR_London http…
ICYMI: Targeting p300/CBP in lethal #prostatecancer. @AdamSharpMedOnc @Nb10Nigel @NeilPegg1 @royalmarsdenNHS @ICR_London https://t.co/IbeoG64BFC https://t.co/r9CaAVO1HM
Targeting p300/CBP axis in lethal prostate cancer. 𝘾𝙖𝙣𝙘𝙚𝙧 𝘿𝙞𝙨𝙘𝙤𝙫. #ProstateCancer https://t.co/VgGOOloli7
RT @SKCCDirector: First study from what has been an incredible collaboration with @ICR_London + @CellCentric. Excited about the p300/CBP br…
RT @CellCentric: Great collaborative effort with @ICR_London and @TJUHospital @SKCCDirector: new strategy to treat prostate cancer through…
RT @SKCCDirector: First study from what has been an incredible collaboration with @ICR_London + @CellCentric. Excited about the p300/CBP br…
RT @SKCCDirector: First study from what has been an incredible collaboration with @ICR_London + @CellCentric. Excited about the p300/CBP br…
RT @SKCCDirector: First study from what has been an incredible collaboration with @ICR_London + @CellCentric. Excited about the p300/CBP br…
RT @SKCCDirector: First study from what has been an incredible collaboration with @ICR_London + @CellCentric. Excited about the p300/CBP br…
RT @SKCCDirector: First study from what has been an incredible collaboration with @ICR_London + @CellCentric. Excited about the p300/CBP br…
First study from what has been an incredible collaboration with @ICR_London + @CellCentric. Excited about the p300/CBP bromodomain as a therapeutic target for #prostatecancer. TY @PCF_Science for supporting the science & kudos to the De Bono + Knudsen
RT @CellCentric: Great collaborative effort with @ICR_London and @TJUHospital @SKCCDirector: new strategy to treat prostate cancer through…
RT @CellCentric: Great collaborative effort with @ICR_London and @TJUHospital @SKCCDirector: new strategy to treat prostate cancer through…
RT @ElizSMcKenna: Now online in @CD_AACR: Targeting p300/CBP in lethal #prostatecancer @AdamSharpMedOnc @Nb10Nigel @NeilPegg1 @royalmarsden…
RT @ElizSMcKenna: Now online in @CD_AACR: Targeting p300/CBP in lethal #prostatecancer @AdamSharpMedOnc @Nb10Nigel @NeilPegg1 @royalmarsden…
RT @DrAbhiPal: Excited to see this published in @CD_AACR and to have been part of the excellent research team lead by Johann De Bono and @A…
RT @Nb10Nigel: Delighted that our paper describing the pharmacology and application of CCS1477, our first in class inhibitor of p300/CBP, i…
RT @Nb10Nigel: Delighted that our paper describing the pharmacology and application of CCS1477, our first in class inhibitor of p300/CBP, i…
RT @IainFrame: A great example of multinational, multiagency research producing the goods to benefit patients. Specially pleased to see sup…
RT @Kaochar2: Major breakthrough! Fantastic achievement from Cell Centric in collaboration with De Bono & Knudsen groups. CCS1477 Early Pha…
RT @DrAbhiPal: Excited to see this published in @CD_AACR and to have been part of the excellent research team lead by Johann De Bono and @A…
RT @DrAbhiPal: Excited to see this published in @CD_AACR and to have been part of the excellent research team lead by Johann De Bono and @A…
A great example of multinational, multiagency research producing the goods to benefit patients. Specially pleased to see support from the @NCRI_partners, @CR_UK and @ProstateUK and that of @ECMC_UK and @CellCentric working together with @Movember and @PCF_
RT @Nb10Nigel: Delighted that our paper describing the pharmacology and application of CCS1477, our first in class inhibitor of p300/CBP, i…
RT @CD_AACR: Just published #OnlineFirst: Targeting p300/CBP in lethal #prostatecancer. @AdamSharpMedOnc @Nb10Nigel @NeilPegg1 @royalmarsd…
RT @Kaochar2: Major breakthrough! Fantastic achievement from Cell Centric in collaboration with De Bono & Knudsen groups. CCS1477 Early Pha…
RT @ElizSMcKenna: Now online in @CD_AACR: Targeting p300/CBP in lethal #prostatecancer @AdamSharpMedOnc @Nb10Nigel @NeilPegg1 @royalmarsden…
RT @CD_AACR: Just published #OnlineFirst: Targeting p300/CBP in lethal #prostatecancer. @AdamSharpMedOnc @Nb10Nigel @NeilPegg1 @royalmarsd…
Major breakthrough! Fantastic achievement from Cell Centric in collaboration with De Bono & Knudsen groups. CCS1477 Early Phase I looks promising. Looking forward to US/other sites opportunities!! @jodebon @SKCCDirector @Nb10Nigel @AdamSharpMedOnc @PCF
RT @CellCentric: Just published: cornerstone publication in Cancer Discovery: targeting p300/CBP with novel drug CCS1477 to treat prostate…
RT @CD_AACR: Just published #OnlineFirst: Targeting p300/CBP in lethal #prostatecancer. @AdamSharpMedOnc @Nb10Nigel @NeilPegg1 @royalmarsd…
RT @ElizSMcKenna: Now online in @CD_AACR: Targeting p300/CBP in lethal #prostatecancer @AdamSharpMedOnc @Nb10Nigel @NeilPegg1 @royalmarsden…
RT @ElizSMcKenna: Now online in @CD_AACR: Targeting p300/CBP in lethal #prostatecancer @AdamSharpMedOnc @Nb10Nigel @NeilPegg1 @royalmarsden…
Just published #OnlineFirst: Targeting p300/CBP in lethal #prostatecancer. @AdamSharpMedOnc @Nb10Nigel @NeilPegg1 @royalmarsdenNHS @ICR_London https://t.co/w0c6ti6npt https://t.co/yUFFkj4jLC
RT @ElizSMcKenna: Now online in @CD_AACR: Targeting p300/CBP in lethal #prostatecancer @AdamSharpMedOnc @Nb10Nigel @NeilPegg1 @royalmarsden…
RT @Nb10Nigel: Delighted that our paper describing the pharmacology and application of CCS1477, our first in class inhibitor of p300/CBP, i…
RT @DrAbhiPal: Excited to see this published in @CD_AACR and to have been part of the excellent research team lead by Johann De Bono and @A…
RT @Nb10Nigel: Delighted that our paper describing the pharmacology and application of CCS1477, our first in class inhibitor of p300/CBP, i…
RT @DrAbhiPal: Excited to see this published in @CD_AACR and to have been part of the excellent research team lead by Johann De Bono and @A…
RT @ElizSMcKenna: Now online in @CD_AACR: Targeting p300/CBP in lethal #prostatecancer @AdamSharpMedOnc @Nb10Nigel @NeilPegg1 @royalmarsden…
Great news!
RT @DrAbhiPal: Excited to see this published in @CD_AACR and to have been part of the excellent research team lead by Johann De Bono and @A…
RT @Nb10Nigel: Delighted that our paper describing the pharmacology and application of CCS1477, our first in class inhibitor of p300/CBP, i…
Now online in @CD_AACR: Targeting p300/CBP in lethal #prostatecancer @AdamSharpMedOnc @Nb10Nigel @NeilPegg1 @royalmarsdenNHS @ICR_London https://t.co/TjiQPGNk0X
Congratulations
RT @CellCentric: Great collaborative effort with @ICR_London and @TJUHospital @SKCCDirector: new strategy to treat prostate cancer through…
RT @CellCentric: Great collaborative effort with @ICR_London and @TJUHospital @SKCCDirector: new strategy to treat prostate cancer through…
New cancer target, first-in-class drug. Cornerstone publication out today: https://t.co/PSmyG9naG2 Concept to lab, drug discovery and development; fantastic wide team effort over many years; collaborative scientists, CROs, consultants, hospitals and fund
Great collaborative effort with @ICR_London and @TJUHospital @SKCCDirector: new strategy to treat prostate cancer through targeting p300/CBP. https://t.co/PF3WkwQNmx https://t.co/CLWvY2CZk2
Excited to see this published in @CD_AACR and to have been part of the excellent research team lead by Johann De Bono and @AdamSharpMedOnc at the Drug Development Unit @royalmarsdenNHS @ICR_London looking at a novel target in prostate cancer @AnthonyMJoshu
RT @Nb10Nigel: Delighted that our paper describing the pharmacology and application of CCS1477, our first in class inhibitor of p300/CBP, i…
RT @Kidlington: #PYC long standing client / partner on #CCS1477 https://t.co/sGto2qVoL7
RT @CellCentric: Just published: cornerstone publication in Cancer Discovery: targeting p300/CBP with novel drug CCS1477 to treat prostate…
Just published: cornerstone publication in Cancer Discovery: targeting p300/CBP with novel drug CCS1477 to treat prostate cancer. https://t.co/PF3WkwQNmx https://t.co/nSmaio78f0
Delighted that our paper describing the pharmacology and application of CCS1477, our first in class inhibitor of p300/CBP, is now published. Wonderful collaborations and great team science have got us here. https://t.co/OSQBQFPspo
RT @whlwest: Just published: cornerstone publication in Cancer Discovery: targeting p300/CBP with novel drug CCS1477 to treat prostate canc…
Just published: cornerstone publication in Cancer Discovery: targeting p300/CBP with novel drug CCS1477 to treat prostate cancer. https://t.co/PSmyG9naG2 https://t.co/bg0Z4GeMuo